Novo Nordisk A/S
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Research Study Investigating How Well NDec Works in People With Sickle Cell Disease
- Conditions
- Interventions
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 84
- Registration Number
- NCT05405114
- Locations
- 🇺🇸
Jacobi Medical Center, Bronx, New York, United States
🇺🇸Mount Sinai School of Medicine, New York, New York, United States
🇺🇸East Carolina University_Greenville_0, Greenville, North Carolina, United States
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight
- Conditions
- Interventions
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1200
- Registration Number
- NCT05394519
- Locations
- 🇺🇸
John Muir Physicians Network, Concord, California, United States
🇺🇸Headlands Research California, LLC, Escondido, California, United States
🇺🇸St. Jos Heritage Hlthcr_Fllrtn, Fullerton, California, United States
A Research Study of How the Medicine Ziltivekimab Works in the Body of Chinese Men and Women With Kidney Disease and Inflammation
- Conditions
- Interventions
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT05379829
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
🇨🇳Chinses PLA General Hospital, Beijing, Beijing, China
🇨🇳Beijing Hospital, Beijing, Beijing, China
A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity
- Conditions
- Interventions
- First Posted Date
- 2022-05-11
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 144
- Registration Number
- NCT05369390
- Locations
- 🇺🇸
ICON Early Phase Services, LLC, San Antonio, Texas, United States
🇺🇸Novo Nordisk Investigational Site, San Antonio, Texas, United States
A Research Study Investigating Nonacog Beta Pegol (N9-GP) for Treatment and Prevention of Bleedings in Chinese People With Haemophilia B
- First Posted Date
- 2022-05-09
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 30
- Registration Number
- NCT05365217
- Locations
- 🇨🇳
The Affiliated hospital of Guizhou Medical University-Hemato, Guiyang, Guizhou, China
🇨🇳Beijing Children's Hospital，Capital Medical University, Beijing, Beijing, China
🇨🇳Fujian Medical University Union Hospital-Hematology, Fuzhou, Fujian, China
A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes.
- Conditions
- Interventions
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 162
- Registration Number
- NCT05363774
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
🇩🇰Novo Nordisk Investigational Site, Søborg, Denmark
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec
- First Posted Date
- 2022-04-29
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1291
- Registration Number
- NCT05352815
- Locations
- 🇺🇸
AM Diabetes And Endocrinology Center, Bartlett, Tennessee, United States
🇲🇽Hospital Universitario Dr. José Eleuterio González_Monterrey, Monterrey, Nuevo León, Mexico
🇿🇦Deepak Lakha, Johannesburg, Gauteng, South Africa
A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation II
- Conditions
- Interventions
- First Posted Date
- 2022-04-18
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 152
- Registration Number
- NCT05333107
- Locations
- 🇺🇸
Altasciences Clinical Los Angeles, Inc., Los Angeles, California, United States
🇺🇸Altasciences, Cypress, California, United States
A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow
- Conditions
- Interventions
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 399
- Registration Number
- NCT05330325
- Locations
- 🇵🇱
Klinika Endokrynologii i Chorób Metabolicznych, Lodz, Poland
🇸🇮University Children's Hospital, Ljubljana, Slovenia
🇺🇸Univ of AL at Birmingham_BRM, Birmingham, Alabama, United States
Glycaemic Control and Other Clinical Parameters in Adult Type 2 Diabetes Patients on Basal Insulin Initiating Treatment With IDegLira in Routine Clinical Practice in Colombia
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2022-11-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 175
- Registration Number
- NCT05324462
- Locations
- 🇨🇴
Novo Nordisk Investigational Site, Bucaramanga, Santander, Colombia